Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5283141 | 0.91 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL12313207 | 0.91 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL11911762 | 0.91 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL10237767 | 0.91 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Hydrochloric Acid SCHEMBL21767825 | 0.88 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL12313165 | 0.84 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL11911745 | 0.84 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL2637713 | 0.84 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL3563911 | 0.84 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL2819451 | 0.83 | KCNH2 (0.68) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877745-B2 | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-20130123241-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123241-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | CCR2, CXCR2, CYSLTR2 | SLC6A2 3731/4885SLC6A4 4575/4885SLC6A3 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.